Baxter International (BAX) Getting Somewhat Positive News Coverage, Study Finds
News articles about Baxter International (NYSE:BAX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 46.1102679604509 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Is the Stock Safe to Invest? – Baxter International Inc. (NYSE: BAX) – Alpha Beta Stock (alphabetastock.com)
- Hospitals face shortage of IV bags amid flu outbreak – KTVB (ktvb.com)
- Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain … – Business Wire (press release) (businesswire.com)
- Jan 11, 2018 – Rowland & Co Investment Counsel Buys BB&T Corp … – GuruFocus.com (gurufocus.com)
- Baxter launches its Arisure Closed System Transfer device (dotmed.com)
Several research firms have recently issued reports on BAX. Zacks Investment Research upgraded Baxter International from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Evercore ISI began coverage on Baxter International in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 price target for the company. Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price target for the company in a research note on Wednesday, January 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $65.00 price target on shares of Baxter International in a research note on Thursday, October 26th. Finally, JPMorgan Chase & Co. upgraded Baxter International from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $68.64.
Baxter International (BAX) traded down $0.12 during midday trading on Friday, hitting $68.34. The company had a trading volume of 2,344,711 shares, compared to its average volume of 2,820,000. Baxter International has a fifty-two week low of $45.47 and a fifty-two week high of $69.65. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The firm has a market cap of $37,230.00, a PE ratio of 36.94, a PEG ratio of 2.06 and a beta of 0.69.
Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The business had revenue of $2.71 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter in the previous year, the firm earned $0.56 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. sell-side analysts predict that Baxter International will post 2.43 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.94%. Baxter International’s dividend payout ratio is presently 34.59%.
In related news, SVP Giuseppe Accogli sold 28,641 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jeanne K. Mason sold 33,350 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $65.25, for a total value of $2,176,087.50. Following the transaction, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Insiders have sold a total of 5,061,991 shares of company stock valued at $325,245,035 in the last three months. 0.05% of the stock is owned by insiders.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.